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A B S T R A C T
PDE4 is one of eleven known cyclic nucleotide phosphodiesterase families and plays a pivotal role in
mediating hydrolytic degradation of the important cyclic nucleotide second messenger, cyclic 3050
adenosine monophosphate (cAMP). PDE4 inhibitors are known to have anti-inﬂammatory properties, but
their use in the clinic has been hampered by mechanism-associated side effects that limit maximally
tolerated doses. In an attempt to initiate the development of better-tolerated PDE4 inhibitors we have
surveyed existing approved drugs for PDE4-inhibitory activity. With this objective, we utilised a high-
throughput computational approach that identiﬁed moexipril, a well tolerated and safe angiotensin-
converting enzyme (ACE) inhibitor, as a PDE4 inhibitor. Experimentally we showed that moexipril and two
structurally related analogues acted in the micro molar range to inhibit PDE4 activity. Employing a FRET-
based biosensor constructed from the nucleotide binding domain of the type 1 exchange protein activated
by cAMP, EPAC1, we demonstrated that moexipril markedly potentiated the ability of forskolin to increase
intracellular cAMP levels. Finally, we demonstrated that the PDE4 inhibitory effect of moexipril is
functionally able to induce phosphorylation of the small heat shock protein, Hsp20, by cAMP dependent
protein kinase A. Our data suggest that moexipril is a bona ﬁde PDE4 inhibitor that may provide the starting
point for development of novel PDE4 inhibitors with an improved therapeutic window.
 2013 Elsevier Inc. All rights reserved.
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The escalating costs and diminishing returns of drug develop-
ment have fuelled a growing focus on drug repositioning in recent
years [1]. As annual approvals of new molecular entities (NMEs)
dwindle in the face of increasing economic and regulatory
pressures [2], greater emphasis is being placed on the development
of systematic approaches for identiﬁcation of compounds with
repositioning potential, including the application of in silico
structure-based and chemoinformatic methodologies [3–5]. We
have used such approaches to ﬁnd novel inhibitors of the
important cAMP hydrolyzing phosphodiesterase 4 (PDE4) enzyme
family, which has been implicated in the pathophysiology
underlying a range of diseases and conditions that include
schizophrenia, stroke and asthma [6].* Corresponding author. Tel.: +44 01413301662.
E-mail address: george.baillie@glasgow.ac.uk (G.S. Baillie).
1 These authors are considered as joint ﬁrst authors.
0006-2952/$ – see front matter  2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.bcp.2013.02.026PDE4 is one of eleven known phosphodiesterase families and
plays a pivotal role in mediating hydrolytic degradation of the
important cyclic nucleotide second messenger, cyclic AMP
(cAMP) [7]. The PDE4 family acts to regulate downstream
signalling events induced by cAMP, and does so via the action of
approximately 25 different isoforms that arise as multiple splice
variants encoded by four distinct genes (PDE4A, B, C and D) [8].
The fact that all PDE4 enzymes have been highly conserved over
evolution suggests that they have non-redundant functional
roles in regulating cAMP homeostasis linked to the compart-
mentalisation of cAMP signalling [9]. As all PDE4 isoforms have
similar Km and Vmax parameters for cAMP hydrolysis, their
functional roles are determined largely by their cellular location
and post-translational modiﬁcation. Discrete intracellular tar-
geting of individual PDE4 isoforms is most often directed by a
‘‘postcode’’ sequence within their unique N-terminal domains
[10], which are responsible for promoting many of the protein–
protein and (in one case) protein–lipid interactions that act to
anchor PDE4s to signalling nodes in sub-cellular compartments
[6].
Fig. 1. Established PDE4 inhibitors (2–6) and newly identiﬁed PDE4-inhibitory 3-carboxy-6,7-dimethoxytetrahydroisoquinoline compounds: moexipril (1a), 7 and 8.
R.T. Cameron et al. / Biochemical Pharmacology 85 (2013) 1297–13051298It is well established that inhibitors targeted to the catalytic
pocket of PDE4s show promise for the treatment of chronic
obstructive pulmonary disease (COPD) and asthma, rheumatoid
arthritis, inﬂammatory bowel disease and psoriasis [11,12].
PDE4 inhibitors have also been shown to be effective in
reversing age associated memory deﬁcits, promoting memory
function and treating depression [13]. Thus, in principle, PDE4
inhibitors have considerable therapeutic potential. In practice,
however, their clinical utility has been compromised by mecha-
nism-associated side effects that limit maximally tolerated doses
[14]. Headache, nausea, emesis and diarrhoea are the most
commonly reported side effects and these stem from the inhibition
of PDE4 activity in non-target tissues. In particular, PDE4D
expression is high in a region of the brain, the area postrema,
where inhibitor action may trigger nausea [14]. Despite the
challenges to therapeutic deployment of PDE4 inhibitors, one such
compound (roﬂumilast, Fig. 1) has recently been approved by the
European Commission and US Food and Drug Administration (FDA)
for the treatment of severe COPD [15], albeit that concern remains
over side-effects such as diarrhoea, pancreatitis and weight loss
associated with its administration [16].
One strategy to develop a novel, safer class of PDE4 inhibitor
would be to survey existing approved drugs for PDE4-inhibitory
activity. With this objective we have used a high-throughput
computational approach to identify moexipril (1a, Fig. 1), a well
tolerated and safe angiotensin-converting enzyme (ACE) inhibitor
[17], as a PDE4 inhibitor. Moexipril may thus, in principle,
constitute a new starting point for development of pharmacologi-
cally useful PDE4 inhibitors.
2. Materials and methods
2.1. Chemical informatics
The 2010 MDL Drug Data Report was used as a source of on
market drugs [18] and each drug was compared to the sets of
ligands for each PDE4 subtype according to ChEMBL [19] withthe Similarity Ensemble Approach [5,20]. The ACE inhibitor
moexipril [21,22] was identiﬁed as a potential PDE4A, B, C and
D inhibitor by SEA, with an E-value of 1.7111 and a max Tanimoto
coefﬁcient in ECFP4 ﬁngerprints of 0.35. Moexipril was tested for
colloidal aggregation [23] by dynamic light scattering where no
particles were observed, additionally it did not inhibit beta-
lactamase at 10 or 100 mM. Searching for analogues of moexipril
was done with ZINC [24]. Docking to PDB Code 1MKD [25] was
performed with DOCK3.6 [26], the best scoring pose that over-
lapped the known ligand was chosen.
2.2. Chemicals
Moexipril, rolipram, KT5720, forskolin, IBMX were bought from
Sigma–Aldrich (UK). Compounds 7 and 8 were purchased from
Princeton BioMolecular Research (USA). All cell culture media, sera
and solutions were purchased from Gibco (Invitrogen Life
Technologies, UK)
2.3. Cell culture
HEK293 cells were maintained in DMEM containing 10% (v/v)
FBS, 2 mM L-glutamine and 1% penicillin/streptomycin. SH-SY5Y
cells were maintained in DMEM:F12 (1:1) containing 10% (v/v)
FBS, 2 mM L-glutamine and 1% penicillin/streptomycin. For FRET
analysis SH-SY5Y cells stably expressing Epac1-camps under G418
selection (500 mg/ml) were seeded onto 22 mm round glass
coverslips and maintained in a 6 well plate 24 h prior to use.
2.4. Transient expression of PDE4 isoforms in HEK293 cells
Expression plasmids encoding human PDE4 were as previously
described by us [27,28]. The plasmids were puriﬁed from
Escherichia coli using the Maxi-prep system (Qiagen, UK). For
transient transfections, HEK293 cells were seeded at a 1:3 ratio
into culture ﬂasks 24 h before transfection so that cells were 60%
conﬂuent by the time of transfection. Transfections were carried
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dance with manufacturer’s instructions.
2.5. Generation of HEK293 cell lysates for PDE assay
Cells (90–100% conﬂuent) were transfected for 48 h with
cDNA encoding PDE4B2, PDE4A5, PDE4D5, PDE8A and PDE5,
washed with PBS and harvested by using a cell scraper in KHEM
buffer (50 mM KCl, 50 mM HEPES; pH 7.2, 10 mM EGTA, 1.92 mM
MgCl2, 1 mM dithiothreitol (DTT)) supplemented with protease
inhibitor Mini-Complete (Roche, UK). Samples were then frozen on
solid CO2, thawed and then manually homogenised, followed by
passage through a 26-gauge needle several times to ensure
complete cell lysis. Cells were centrifuged at 13,000 rpm for 10 min
to remove any unbroken cells, and the resulting supernatant was
frozen in solid CO2 and stored at 80 8C until required. For
experimentation, the protein concentration of whole-cell lysate
from transfected and mock-transfected (vector only) cells was
equalised (typically to 1 mg/ml). Protein concentration was
determined through Bradford Assay using bovine serum albumin
as standard.
2.6. PDE assays
PDE activity was determined using a two-step radioassay
procedure as described previously [29]. Activities for each PDE
subtype were related to a non-drug treated sample (100% control)
over an increasing dose of the indicated compounds. IC50 values
were calculated using. In all cases, the transfected PDE accounted
for over 97% of the total PDE activity when compared with the
untransfected control lysates.
2.7. FRET imaging
FRET imaging experiments were performed on SH-SY5Y-Epac1-
camps stables. Cells were maintained at room temperature in DPBS
(Invitrogen, UK), with added CaCl2 and MgCl2, and imaged on an
inverted microscope (Olympus IX71) with a PlanApoN, 60X, NA
1.42 oil, 0.17/FN 26.5, objective (Japan). The microscope was
equipped with a CCD camera (cool SNAP HQ monochrome,
Photometrics), and a beam-splitter optical device (Dual-channel
simultaneous-imaging system, DV2 mag biosystem (ET-04-EM)).
Imaging acquisition and analysis software used was Meta imaging
series 7.1, Metaﬂuor, and processed using ImageJ (http://rsb.info.-
nih.gov/ij/). FRET changes were measured as changes in the
background-subtracted 480/545-nm ﬂuorescence emission inten-
sity on excitation at 430 nm and expressed as either R/R0, where R
is the ratio at time t and R0 is the ratio at time = 0 s, or DR/R0,
where DR = R  R0. Values are expressed as the mean  SEM.
2.8. Hsp20 phosphorylation assay
SH-SY5Y cells were seeded at a density of 1  106 cell per
well onto 6 well plates (Corning, UK) for at least 16 h prior to
treatment with rolipram (10 mM), moexipril (50 mM), com-
pound 7 (50 mM) and compound 8 (50 mM). Compounds were
diluted in media and added to cells for 0.5, 1 and 2 h prior to
harvesting using 3T3 lysis buffer (1% Triton X-100, 50 mM
Hepes, pH 7.2, 10 mM EDTA and 100 mM NaH2PO4) supple-
mented with protease inhibitor Mini-Complete (Roche) and
phosphatase inhibitor PHOS-stop (Roche, UK). Hsp20 expression
was analysed using standard SDS-PAGE and Western Blotting
techniques using the phospho-Hsp20 antibody (ab58522 Abcam,
UK) and alpha-tubulin-HRP antibody (ab40742 Abcam, UK) as
the loading control. Western blotting for PDE4s was undertaken
using antibodies previously described by us [30].3. Results
3.1. Chemical informatics and docking studies identify moexipril as a
candidate PDE4 inhibitor
The similarity ensemble approach (SEA) is one of a number of in
silico methods now used to identify off-target activity in drugs. The
technique measures the topological similarity between bait
molecules, here for instance moexepril, and a set of ligands
annotated to any given target in a library of target-ligand sets. The
observed similarities between the bait molecule(s) and the ligand-
sets are compared to what would be expected at random, and the
expectation value of seeing the level of similarity observed is
calculated [4,5]. Because SEA compares molecules to annotated
ligands as sets, collective similarity can be established even when
the pair-wise similarity to any single ligand in the set may be
modest. It has been applied successfully to predict activity of
established drugs against previously unreported targets [4,31] and
also used to predict biological activity in natural products [32].
Here we applied SEA to probe the MDL Drug Data Report (MDDR), a
database currently comprising >180,000 biologically relevant
compounds with a focus on drugs that are launched or under
current development. In doing so we identiﬁed moexipril
[21,22,33] as a candidate PDE4 inhibitor, using ChEMBL to examine
known sets of PDE4 active compounds [19]. Though moexipril’s
similarity to even the closest known PDE4 inhibitor was modest – a
Tanimoto coefﬁcient of 0.35 qualiﬁes it as close to a scaffold-hop
for the ECFP4 ﬁngerprints [Ref.: PMID 18416545] – over the entire
PDE4 ligand set its expectation value (E-value), at 1.7111, was
highly signiﬁcant compared to the random background.
3.2. Models of moexipril bound to catalytic domain of PDE4
As the structure of the PDE4 core catalytic domain is well
deﬁned by X-ray crystallography, with numerous co-crystal
structures available for a range of inhibitors from different
structural classes, we additionally undertook the molecular
docking of moexipril to consider its potential as a PDE4 inhibitor.
Docking was carried out with DOCK3.6 [26] against the co-crystal
structure (PDB: 1MKD) of the PDE4D core catalytic domain with
bound zardaverine (2) [25]. In the best scoring pose (Fig. 2A), the
6,7-dimethoxytetrahydroisoquinoline core of moexipril over-
lapped closely with the catechol ether subunit of zardaverine
(2) to engage the purine-scanning glutamine, a residue that is
conserved across the entire PDE superfamily and which ordinarily
anchors the substrate nucleobase during enzymatic turnover.
Catechol ethers such as zardaverine [34] constitute one of the main
PDE4 inhibitor chemotypes and include rolipram (3) [35], the
archetypal PDE4-selective inhibitor, as well as the isoquinoline
natural product, papaverine (4) [36]. The recently approved ﬁrst-
in-class PDE4 inhibitor, roﬂumilast (5) [37], and other compounds
such cilomilast (6) [38] that have progressed to clinical trials also
possess a catechol ether core structure. Numerous co-crystal
structures are available for this class of PDE4 inhibitor [25,39,40],
and in all cases the catechol ether oxygen atoms straddle the Ne
centre of the purine-scanning Gln, forming convergent hydrogen
bonds in the manner predicted for the docked moexipril model.
The 3-carboxy group of the ligand in this pose would be orientated
proximal to the bimetallic catalytic centre of the enzyme, whilst
the side chain extension would be free to run across the
hydrophobic rim of the catalytic pocket with little constraint.
3.3. Biochemical determination moexipril potency as PDE4 inhibitor
To test the prediction that moexipril might exhibit PDE4-
inhibitory activity, we assayed the compound for inhibition of
Fig. 2. Docked models of newly identiﬁed 3-carboxy-6,7-dimethoxytetrahydroisoquinoline inhibitors [moexipril (1a), 7 and 8] ﬁtted to the PDE4 catalytic pocket and
comparison with papaverine (4). (A)–(C) Best scoring poses for moexipril, 7 and 8 docked into the PDE4 zardaverine co-crystal structure (PDE4: 1MKD). (D) Structure of
papaverine (cyan stick) bound to PDE4D core catalytic domain (PDB: 3IAK). (E) and (F) models of inhibitor 8 (green stick) ﬁtted to the PDE4 papaverine co-crystal structure
showing poses with alternative conformations for the tetrahydroisoquinoline core. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of the article.)
Fig. 3. Determination of the efﬁcacy of established and novel PDE4 inhibitors. Activities for each PDE4 subtype were related to a non-drug treated sample (100% control) over
an increasing dose of the indicated compounds (n = 3). IC50 values were calculated using Graphpad Prism 4.0. (A) Dose response curves of moexipril against 3 different PDE4
isoforms. (B) Dose response curves of four different PDE4 inhibitors against PDE4B2. (C) Dose response curves of moexipril against PDE8A1 and PDE5.
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PDE4D5. Moexipril inhibited cAMP hydrolysis by all three isoforms
in the micromolar range (Fig. 3A), but was most potent against the
PDE4B2 isoform (IC50 38 mM), with PDE4A4 and PDE4D5 showing
respectively 4-fold and 6-fold lower sensitivity to inhibition.
Having conﬁrmed the prediction that moexipril should inhibit
PDE4, we next undertook a search for other commercially available
3-carboxy-6,7-dimethoxytetrahydroisoquinolines using ZINC [24].
Our search identiﬁed two compounds (7 and 8) possessing the
tetrahydroisoquinoline core of moexipril but with simpliﬁed N-
acyl extensions. Both compounds were available in racemic form
from screening vendors and initial docking studies, undertaken
with the (S)-conﬁgured structures, suggested that the PDE4
catalytic pocket should be able to accommodate these compounds,
with the N-acyl side chains extending across its rim (Fig. 2B and C).
The (S)-enantiomers were selected for docking in order to match
the absolute conﬁguration at the tetrahydroisoquinoline 3-
position of moexipril. The inhibitory activity of (rac)-7 and (rac)-
8 was then assessed using PDE4B2, selected as the isoform thatFig. 4. Utilisation of a cAMP reporter construct to visualise changes in cAMP concentrati
based biosensor constructed from the nucleotide binding domain of the type 1 exchang
application of forskolin (FSK), followed by treatment with PDE4 inhibitors (i) rolipram (R
Data is from a single cell and is representative of experiments carried out at least n = 15. (
lane 6 a saturating dose of forskolin (25 mM) plus the general PDE inhibitor 3-isobutyl-
Signiﬁcance evaluated using Student’s t-test, ***p < 0.001 when compared with FSK alonexhibited greatest sensitivity to inhibition by moexipril, Fig. 3B.
The archetypal inhibitor, rolipram (3), was included in this
comparative evaluation as a positive control. Consistent with
the modelling, both of the moexipril analogues inhibited PDE4B2.
Compound 8 showed the highest afﬁnity for PDE4, having an IC50 of
6.9 mM, 7-fold better than moexipril, while compound 7 had an
IC50 89 mM. The inhibition curves suggest a binding mode that is
competitive with cAMP for the catalytic site of the enzyme,
consistent with the docked models (Fig. 2). By comparison, (rac)-
rolipram, a drug optimised for this enzyme, had an IC50 1 mM
against it. Moexipril showed no activity against two other PDE
family members, PDE8A and PDE5, suggesting that it could act as a
PDE4 speciﬁc inhibitor (Fig. 3).
3.4. Moexipril induces cAMP increase in cells
To determine whether the inhibition of PDE4 by moexipril and
its analogues (7 and 8) could induce cellular increases in cAMP, we
employed a FRET-based biosensor constructed from the nucleotideon triggered by PDE4 inhibitors. (A) Diagram illustrating mode of action of a FRET-
e protein activated by cAMP, EPAC1. (B) Changes in FRET ratio triggered by a 5 mM
oli), (ii) moexipril (Moex), (iii) compound 7 (Cmp 7), and (iv) compound 8 (Cmp 8).
C) Quantiﬁcation of mean change in FRET ratio for all of the treatments including in
1-methylxanthine (IBMX 100 mM). All other lanes forskolin (FSK) applied at 5 mM.
e. Number of individual experiments denoted by white numbers within grey bars.
Fig. 5. PDE4 inhibitors induce PKA phosphorylation of the small heat-shock protein
Hsp20. Lysates from SH-SY5Y cells were blotted for the expression of endogenous
(A) PDE4D and (B) PDE4B enzymes. SH-SY5Y cells were treated with (C) rolipram
(10 mM), (D) moexipril (50 mM), (E) compound 7 (50 mM) and (F) compound 8
(50 mM) for the indicated times. Cell lysates subjected to SDS page and western
blotting. Blots were probed for phospho-serine 16 on Hsp20 and a loading control
(tubulin). Quantiﬁcation (n = 3) of the relative amounts of phosphorylation on
serine 16 vs loading control were calculated following densitometry. Results are
plotted as a percentage of the maximal phosphorylation over time. Signiﬁcance
evaluated using Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001. (G) SH-SY5Y
cells were treated with KT5720 (4 mM) 20 min before the addition of a sub-optimal
dose of forskolin (FSK, 10 mM) or forskolin (FSK, 10 mM) with moexipril (Moex,
50 mM) for 5 min. Lysates were blotted for tubulin or phospho-serine 16 on Hsp20.
Data representative of n = 3.
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EPAC1 [41] (see Fig. 4A). This probe enables quantitative, real-time
detection of rapid changes in bulk cAMP following cell treatment.
Experiments were done using SH-SY5Y cells stably expressing the
biosensor. This cell line endogenously expresses PDE4 isoforms
from the PDE4B and PDE4D subfamilies (Fig. 5A and B) [42]. All
compounds markedly increased cellular cAMP levels over those
induced by treatment with a sub-maximal dose of the adenylyl
cyclase activator, forskolin alone (Fig. 4B–E). No FRET changes were
detected when the compounds were added alone. The FRET ratio
changes we observe here (Fig. 4F), are in line with those previously
published for rolipram potentiation of the forskolin-stimulated
cAMP response [41]. That the magnitude of cAMP response
produced by moexipril and analogues evaluated here, is similar to
that produced by rolipram further supports the notion that the ACE
inhibitor could, in principle, also act as an in vivo PDE4 inhibitor.
3.5. Moexipril treatment triggers PKA phosphorylation of Hsp20
To evaluate whether, under the conditions of our in vitro
studies, the elevation in global cAMP triggered by moexipril and
analogues also resulted in downstream signalling events driven by
the cAMP-effector protein, protein-kinase A (PKA), we studied a
phosphorylation event recently attributed to the kinase. The small
heat shock protein Hsp20 (HspB6) is a chaperone protein, which
combats a number of pathophysiological processes in the heart,
vasculature and brain [43]. The protective actions of Hsp20 require
its phosphorylation by PKA on serine 16. Its association with PDE4
[44], however, keeps cAMP levels surrounding Hsp20 low,
maintaining Hsp20 in its basal, unphosphorylated state. Thus
association with PDE4 prevents inappropriate phosphorylation
and activation of Hsp20 by ﬂuctuations in basal cAMP levels. A
similar protective ‘gating’ effect through PKA sequestration has
been observed for AKAP-anchored PKA in the centrosome [45].
The PKA phosphorylation of Hsp20 was chosen here as a
readout for physiological PDE4 inhibition as it has been shown
previously that PDE4 inhibition alone via the action of rolipram,
could trigger this phosphorylation event without the need for
artiﬁcially raising cAMP with sub-optimal doses of forskolin to
activate adenylyl cyclase [44]. We thus monitored the transient
phosphorylation status of Hsp20 in SH-SY5Y cells following
treatment of cells with either rolipram, or moexipril, or moexipril
analogues 7 and 8 (Fig. 5C, D, E and F respectively). As previously
observed with rolipram treatment [44], challenge of cells with any
of three 3-carboxy-6,7-dimethoxytetrahydroisoquinoline analo-
gues signiﬁcantly elevated Hsp20 phosphorylation. The temporal
nature of Hsp20 phosphorylation induction differed somewhat
between compounds. However, this is likely to reﬂect differences
in their potency in elevating cAMP levels, where rolipram induces
the largest increase in cAMP (Fig. 4F) and triggers the most rapid
Hsp20 phosphorylation (Fig. 5A). The transient nature of phos-
phorylation following treatment is likely to be attributed to
compensatory mechanisms employed by the cell to combat cAMP
increases, mechanisms that include activation of PDE4 enzymes by
PKA [28] and dephosphorylation of Hsp20 by as yet unknown
phosphatases. To prove that the observed phosphorylations were
PKA dependent, a PKA speciﬁc inhibitor (KT5720) was used to
attenuate the phosphorylation of HSP20 induced by moexipril and
a sub-optimal dose of forskolin (Fig. 5G).
4. Discussion
Moexipril (1a) was originally developed as a long-acting,
nonsulfhydryl angiotensin-I converting enzyme (ACE) inhibitor
suitable for once-daily administration [33]. The drug is used to
treat hypertension and is well tolerated, apparently lackingemetogenic activity [21,22]. Although moexipril itself has ACE-
inhibitory activity in its own right, it serves as a prodrug for the
more potent metabolite, moexiprilat (1b, Fig. 1), generated in vivo
by hydrolysis of the side chain ester. PDE4-inhibitory activity has
not previously been attributed to moexipril, but we identiﬁed the
compound as a candidate PDE4 inhibitor by screening the MDDR
drug database using the chemoinformatics SEA method. This
prediction was further supported by molecular docking studies.
These suggested that moexipril may feasibly bind to the PDE4
catalytic pocket with its methoxy groups engaging the purine-
scanning Gln in a manner similar to the binding mode adopted by
the catechol ether class of PDE4 inhibitors. Indeed moexipril is
structurally related to the 6,7-dimethoxyisoquinoline natural
product, papaverine (4), an established phosphodiesterase
R.T. Cameron et al. / Biochemical Pharmacology 85 (2013) 1297–1305 1303inhibitor of the catechol ether class for which a PDE4 co-crystal
structure (PDB: 3IAK) has been determined (Fig. 2D).
To test the prediction that moexipril may inhibit PDE4 we
evaluated its effect in assays using PDE4A4, PDE4B2 and PDE4D5,
three ubiquitously expressed isoforms of the PDE4 family [6].
Encouragingly, our initial assessment conﬁrmed that moexipril
possesses PDE4-inhibitory activity in the enzyme assays (but not
against PDE8A or PDE5). Furthermore, the inhibition of endoge-
nous PDE4 isoforms by moexipril was evaluated using a cytosolic
Epac-based FRET probe and was shown to signiﬁcantly enhance
intracellular cAMP increases triggered by forskolin treatment.
Epac-based FRET probes require association of only one cAMP
molecule to alter FRET ratios by up to 30% and they also exhibit fast
activation kinetics that allow ‘‘realtime’’ evaluation of cAMP
dynamics [46]. As the probes are not localised to any intracellular
domains [41], the readout reﬂects changes in ‘‘global’’ cAMP
concentrations and this is appropriate as we show that moexipril
has activity against multiple PDE4 isoforms (Fig. 3) that are known
to target, via unique N-terminal sequences, multiple and distinct
cellular locations [9,10].
To demonstrate that cAMP increases initiated by the action of
moexipril on PDE4s could result in downstream physiological
consequences in cells, we monitored changes in the phosphor-
ylation of a well-characterized PKA substrate, Hsp20 [43]. Hsp20
is readily phosphorylated by PKA as it exists in a complex with
the A-kinase anchoring protein (AKAP), AKAP-Lbc [47]. However
the activity of this Hsp20 anchored pool of PKA is tonically
inhibited by sequestered PDE4 that also interacts with Hsp20
[44]. These features make Hsp20 uniquely sensitive to PKA
phosphorylation following PDE4 inhibition, even under basal
cAMP conditions. Both rolipram and moexipril signiﬁcantly
increased phospho-Hsp20 levels when compared with untreated
cells, though the maximal effect was reached earlier with
rolipram (Fig. 5). This is consistent with the other data we
present, showing that rolipram challenge results in larger
cellular increases in cAMP than does moexipril (Fig. 4F).
Moexiprilat (1b) was not readily available commercially and
consequently we were unable to evaluate it for PDE4-inhibitory
activity. Instead we searched for other commercially available 3-
carboxy-6,7-dimethoxytetrahydroisoquinoline analogues in order
to expand the study. Two compounds (7 and 8) were identiﬁed
with no prior literature or patent associations and thus no
previously reported biological or pharmacological activity. The
compounds were sourced and tested in racemic form using
PDE4B2, the latter chosen because, of the three isoforms used in
our preliminary study, it had proven most sensitive to inhibition by
moexipril. Indeed, both compounds showed activity, with ana-
logue 8 exhibiting low micromolar potency (Fig. 3). In keeping with
their ability to inhibit PDE4, both compounds also signiﬁcantly
enhanced intracellular cAMP increases triggered by forskolin
challenge (Fig. 4) and induced Hsp20 phosphorylation (Fig. 5).
Docking of the (S)-enantiomers of both 7 and 8 conﬁrmed that
the 3-carboxy-6,7-dimethoxytetrahydroisoquinoline could ﬁt the
PDE4 catalytic pocket, whilst allowing the N-acyl side chain to
roam over the hydrophobic rim of the pocket. As compounds 7 and
8 were sourced in racemic form, we cannot say to what extent the
activity resides with the (S)-conﬁgured 3-carboxytetrahydroiso-
quinoline ring. Our preliminary docking studies have suggested
that both enantiomers of 7 and 8 might potentially be accommo-
dated in the PDE4 catalytic pocket and further studies would,
therefore, be required to evaluate the eudismic ratio for these
compounds. This is potentially an important point because the
absolute conﬁguration at the C-3 stereocentre of the tetrahydroi-
soquinoline core could signiﬁcantly affect any ACE-inhibitory
activity displayed by these simpliﬁed by moexipril analogues.
Thus, although there is currently no ACE moexiprilat co-crystalstructure available, inspection of co-crystal structures for closely
related ‘pril’ family ACE inhibitors, such as enalaprilat (PDB: 1UZE)
[48], suggests that ACE inhibition should show strong dependence
on the absolute (S)-conﬁguration for the moexipril(at) tetrahy-
droisoquinoline core. In particular, the carboxyl group of
enalaprilat is directed into a pocket lined by Gln, Tyr and Lys
residues that form tight hydrogen bonded and salt bridge
interactions. Access to this pocket will be dependent on the
absolute conﬁguration of the stereocentre in the moexipril(at)
tetrahydroisoquinoline subunit. The side chain carboxylate of
moexiprilat is also expected to make a strong contribution to the
compound’s ACE-inhibitory activity, as (by analogy to enalaprilat)
it should serve as a ligand to the zinc(II) catalytic centre of the
enzyme. Thus, simpliﬁcation of the N-acyl extension in compounds
7 and 8 is expected to substantially reduce any ACE-inhibitory
behaviour. In short, the nature of the N-acyl side chain as well as
the absolute conﬁguration of the 3-carboxy-6,7-dimethoxytetra-
hydroisoquinoline core is likely to have a profound inﬂuence on
ACE inhibition, and these features might be exploited to develop
related compounds as PDE4 inhibitors without ACE-inhibitory
activity. We have not tested 7 and 8 for ACE inhibition in the
present study however.
The nature of the N-acyl side chain clearly also exerts a
signiﬁcant inﬂuence over the PDE4-inhibitory performance of the
compounds that we have identiﬁed here. At present we cannot
precisely rationalise this because the side chain extends from
the opening of the catalytic pocket (Fig. 2E and F) and there is some
ﬂexibility in the potential contact that it might make with the
protein. The rim of the PDE4 catalytic pocket presents an
extensive hydrophobic surface, and many inhibitors with exten-
sions projecting from a core bound within the pocket fold across
this sticky surface, as illustrated in Fig. 2D for papaverine (where
the pendent dimethoxybenzyl side chain fulﬁls this role).
In addition to the ambiguity regarding the position adopted by
the side chain in the PDE4-bound state, there may be more than one
conformation possible for the N-acyl tetrahydroisoquinoline core.
The best scored binding poses generated from the modelling
software (DOCK) orientated the 3-carboxyl group proximal to the
enzyme’s catalytic metal ions (Fig. 2A–C). With this organisation the
ionised carboxylate might directly act as a ligand on the more deeply
sited (zinc) ion or potentially hydrogen bond to water ligands on the
metal centres. The adoption of this bound pose, illustrated for
compound 8 in Fig. 2E, introduces a degree of strain into the
tetrahydroisoquinoline subunit. An alternative conformer, with less
ring strain, would possess a pseudoaxial carboxyl group, as shown in
Fig. 2F. In this case the N-acyl group is predicted to hydrogen bond to
water ligands on the metal centres and also to the proximal His
residue (labelled in Fig. 2D) that plays a role in PDE4 catalysis by
protonating the nucleotide 30-O during substrate turnover. We
cannot at present deﬁnitively indicate which of these two
possibilities will be favoured for the bound compounds. The binding
pose presented in Fig. 2F positions the carboxyl group into a
hydrophobic subpocket in the roof of the substrate binding site, but
it offers a signiﬁcantly more relaxed conformation to the tetra-
hydroisoquinoline. In principle, with this conformation, replace-
ment of the polar carboxyl group by a small hydrophobic substituent
might enhance the afﬁnity and PDE4-inhibitory potency of the
compound, and we have previously used precisely this design
principle in the development of another PDE4 inhibitor series [49].
Given the PDE4-inhibitory activity exhibited by moexipril, it is
not entirely clear why the compound apparently lacks the typical
side effects associated with PDE4 inhibitors. This could be due to its
ADME properties, since neither moexipril nor moexiprilat is brain-
penetrant. However, the dosing window may also play a role in the
reported tolerance of moexipril. Thus, in one PK assessment Cmax
for moexipril was determined at 25 mg/L (50 nM) from an oral
R.T. Cameron et al. / Biochemical Pharmacology 85 (2013) 1297–13051304dose of 15 mg, clinical trials having focused on once-daily dosing
regimens in the 7.5–30 mg range. The negative charge character of
the ionised moexipril and moexiprilat structures may be a
contributory factor underlying their poor uptake by the brain, as
with the carboxyl-bearing second generation PDE4 inhibitor,
cilomilast (6), for which brain penetration is also limited [50].
Thus, retention of the 3-carboxyl group may be a consideration if a
non-emetogenic PDE4 inhibitor series is to be developed from
moexipril.
A key underlying driver behind the work described here was to
identify previously approved drugs that lack any emetogenic
liability as PDE4 inhibitors. Such compounds might either have
direct potential for repositioning as PDE4 inhibitors or provide the
starting point for development of novel PDE4 inhibitors with an
improved therapeutic window. Given that the reported potency
for inhibition of ACE by moexipril [IC50 40 nM vs porcine serum
ACE [21,22]] is some three orders of magnitude greater than for
the inhibition of PDE4 that we disclose here, direct repositioning
of moexipril for indications that might respond to treatment by
PDE4 inhibitors is likely to be problematic. Not least because the
profoundly higher concentrations needed to achieve PDE4
inhibition, compared to those required for ACE inhibition, may
serve also to uncover an emetic response in moexipril. Neverthe-
less, moexipril might constitute a starting point for novel PDE4
inhibitor development, provided that derivatives can be made
that lack an emetogenic proﬁle.
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